Le Lézard
Classified in: Health, Business
Subject: BOARD OF DIRECTORS

Clementia Appoints Industry Executive Shawn Tomasello to its Board of Directors



MONTREAL, July 05, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced the appointment of accomplished industry executive, Shawn Cline Tomasello, to the company's board of directors.

"We are thrilled to have Shawn join Clementia's board of directors at this time. With two late-stage clinical programs advancing in clinical trials, Shawn's broad commercial and strategic leadership experience will be extremely valuable as we plan for potential commercialization," said Clarissa Desjardins, Ph.D., chief executive officer of Clementia.

Ms. Tomasello has extensive strategic experience in building world class organizations encompassing all aspects of commercial and medical affairs functions. Ms. Tomasello most recently served as chief commercial officer of Kite Pharma and was instrumental in building Kite, leading to its acquisition for $11.9 billion by Gilead Pharmaceuticals in 2017. Prior to joining Kite Pharma, Ms. Tomasello served as the chief commercial officer of commercial and medical affairs at Pharmacyclics, and was previously the president of the Americas, hematology and oncology for Celgene Corporation where she led the Company through five successful product launches encompassing eleven indications. Previously, Ms. Tomasello served in leading commercial roles with Genentech and other major pharmaceutical companies. Ms. Tomasello currently serves on the board of directors for Diplomat Pharmacy, Centrexion Therapeutics and Oxford BioTherapeutics.

Ms. Tomasello received her Bachelor of Science in Marketing from the University of Cincinnati and her M.B.A. from Murray State University in Kentucky.

"I am very excited to contribute my knowledge and expertise to the goal of bringing a ground-breaking therapy to patients with FOP and MO," said Ms. Tomasello. "Clementia has rapidly advanced its clinical programs, and I look forward to working with management and the board to bring palovarotene to patients."

Concurrent with Ms. Tomasello's appointment, Clementia also announced that Jean-François Pariseau, MSc, MBA, who has served on the company's board of directors since our seed round in 2012, has stepped down from the board, effective immediately. Clementia wishes to thank Mr. Pariseau for his many contributions over the past six years.

About Clementia Pharmaceuticals Inc.
Clementia is a clinical-stage company innovating new treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company's lead product candidate, palovarotene, a novel RAR? agonist, is currently being evaluated in the Phase 3 MOVE Trial to treat fibrodysplasia ossificans progressiva (FOP) and in the Phase 2 MO-Ped Trial to treat multiple osteochondromas (MO, also known as multiple hereditary exostoses/MHE). Clementia is also investigating palovarotene for the potential treatment of other conditions that may benefit from RAR? therapy. For more information, please visit www.clementiapharma.com and connect with us on Twitter @ClementiaPharma.

Cautionary Note Regarding Forward-Looking Statements
This press release may include "forward-looking statements" within the meaning of the applicable securities laws. Each forward-looking statement contained in this press release is subject to known and unknown risks and uncertainties and other unknown factors that could cause actual results to differ materially from historical results and those expressed or implied by such statement. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Applicable risks and uncertainties include, among others, our ability to generate revenue and become profitable; the risks related to our heavy reliance on palovarotene, our only current product candidate; the risks associated with the development of palovarotene and any future product candidate, including the demonstration of efficacy and safety; our heavy dependence on licensed intellectual property, including our ability to source and maintain licenses from third-party owners; as well as the risks identified under the heading "Risk Factors" in our Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC"), as well as the other information we file with the SEC or on SEDAR. We caution investors not to rely on the forward-looking statements contained in this press release when making an investment decision in our securities. You are encouraged to read our filings with the SEC or on SEDAR, available at www.sec.gov or www.sedar.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of these statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor/Media Contact:
Joseph Walewicz
Clementia Pharmaceuticals Inc.
+1-514-940-1080

Alicia Davis
THRUST Strategic Communications
910-620-3302


These press releases may also interest you

at 12:33
A deep interest in supporting transformative organizational change through the finance function drew Sheila Vokey to the role of Chief Financial Officer at Central 1 Credit Union (Central 1), an appointment the organization is pleased to announce...

at 12:30
The Federal Aviation Administration (FAA) has granted a site operator license to Colorado Air and Space Port after a 180-day review period, the 11th such license granted in the United States. Colorado Air and Space Port will serve as America's hub...

at 12:22
Genuine Parts Company announced today that its Board of Directors declared a regular quarterly cash dividend of seventy two cents ($0.72) per share on the Company's common stock. The dividend is payable October 1, 2018...

at 12:21
To improve quality of life for the residents of the Agglomération de Longueuil and to alleviate road congestion, which is increasing at a phenomenal pace, the municipalities in the agglomeration have united around an integrated vision of public...

at 12:07
On August 20, 2018 the Board of Directors of Chicago Rivet & Machine Co. declared a regular quarterly dividend of twenty one (21) cents per share, payable September 20, 2018 to shareholders of record at the close of business on September 5, 2018....

at 12:06
Fundomate, a leading fintech company focusing on the alternative lending space, and IRIS CRM, a premier merchant services CRM servicing clients in the payment industry, today announced their integration which will enable mutual clients with the...




News published on 5 july 2018 at 06:33 and distributed by: